Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.58 |
| ▸ | ESR1 | P03372 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718137 | 0.84 | HTT (0.55) | ESR2ESR1MEN1MAPTKMT2A | |
| SCHEMBL657801 | 0.84 | HTT (0.55) | ESR2ESR1MEN1MAPTKMT2A | |
| SCHEMBL14754323 | 0.82 | METAP1 (0.49) | MEN1MAPTKMT2AALDH1A1ATM | |
| SCHEMBL31006742 | 0.82 | METAP1 (0.49) | MEN1MAPTKMT2AALDH1A1ATM | |
| SCHEMBL6313863 | 0.79 | ESR1 (0.58) | ESR2ESR1LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL6313985 | 0.78 | KDM4A (0.43) | MAPTPOLBHSD17B1 | |
| SCHEMBL15452653 | 0.76 | METAP1 (0.47) | MEN1MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL29430087 | 0.74 | METAP2 (0.46) | MEN1MAPTKMT2AALDH1A1ATM | |
| SCHEMBL4533675 | 0.74 | METAP2 (0.46) | MEN1MAPTKMT2AALDH1A1ATM | |
| SCHEMBL2920538 | 0.72 | HTT (0.59) | ESR2ESR1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105315319-B | Hepatitis C virus inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-105315319-A | Hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2016-02-10 | — | — | CN | disclosed |
| US-6951876-B2 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1086097-B1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-6603008-B1 | Inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1104760-B1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | ESR2 1120/4885ESR1 2486/4885MEN1 4343/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | ESR2 981/4885ESR1 2282/4885MEN1 4451/4885 |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | ESR2 1120/4885ESR1 2486/4885MEN1 4343/4885 |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PTGS1, PTGS2, SULT2A1 | ESR2 1307/4885ESR1 4399/4885MEN1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.